Aclaris therapeutics to participate in the h.c. wainwright 24th annual global investment conference

Wayne, pa., aug. 30, 2022 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that dr. neal walker, ceo of aclaris, will virtually present a company overview at the h.c. wainwright 24th annual global investment conference, which will be available on-demand beginning on monday, september 12, 2022 at 7:00 a.m. et. management will be available september 12th throughout the day for virtual 1x1 meetings.
ACRS Ratings Summary
ACRS Quant Ranking